<DOC>
	<DOCNO>NCT00966836</DOCNO>
	<brief_summary>Cardiac allograft vasculopathy ( CAV ) major cause long-term graft failure heart transplant recipient . Although several immune-mediated metabolic risk factor implicate pathogenesis CAV , effective therapy currently available treat establish CAV prevent adverse outcome . Therefore , main clinical strategy base prevention treatment factor know trigger development . Although mechanism vague , cytomegalovirus ( CMV ) infection believe play key role CAV progression . Two strategy involve administration specific anti-CMV agent recommend prevention CMV infection/disease : universal prophylaxis preemptive therapy . The pros con two strategy still debate , absence randomize study address graft-related outcome viral mechanism graft damage , without clear evidence superiority either approach . The investigator conceive randomized prospective project compare effect preemptive anti-CMV strategy universal anti-CMV prophylaxis CMV infection one-year increase coronary intimal thickening . Patients additionally randomize receive either mycophenolate mofetil everolimus , light possible anti-CMV property everolimus .</brief_summary>
	<brief_title>Prevention Transplant Atherosclerosis With Everolimus Anti-cytomegalovirus Therapy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Age ≥ 18y Heart heartkidney combine transplant Positive CMV serology time transplant Glomerular filtration rate ≥ 20 ml/min/1.73m2 MDRD randomization . Written inform consent Panel Reactive Antibody ≥50 % Less 1000/mmc neutrophil time randomization Less 30,000/mmc platelet time randomization Clinical significant infection 2 week prior transplant Glomerular filtration rate &lt; 20 ml/min/1.73m2 estimate MDRD formula time randomization hemodialysis treatment Intolerance towards valganciclovir , everolimus , mycophenolate cyclosporine Known contraindication statin use Negative CMV serology time transplant HIV positive test Severe comorbidities , base investigator 's judgment , contraindicate study drug procedure Potentially childbearing woman refuse use contraceptive Participation interventional study 2 preceding week Unwillingness inability follow study procedure sign write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Heart Transplantation</keyword>
	<keyword>Cardiac Allograft Vasculopathy</keyword>
	<keyword>Cytomegalovirus Infection</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Valganciclovir</keyword>
	<keyword>Mycophenolate</keyword>
</DOC>